Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- SystImmune Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06714591
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸START Midwest/The Cancer and Hematology Center, Grand Rapids, Michigan, United States
🇺🇸Oncology Hematology Care Clinical Trials, LLC, Cincinnati, Ohio, United States
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M17D1 in Subjects with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Unresectable Locally Advanced or Metastatic HER2-expressing or HER2-mutant Solid TumorsCohort 1: Subjects with HER2-positive Breast Cancer (BC)Cohort 2: Subjects with HER2-positive Gastric/gastroesophageal Junction Cancer (GC/GEJ)Cohort 3: Subjects with HER2-positive or HER2-mutant Non-small Cell Lung Cancer (NSCLC)Cohort 4: Subjects with HER2-positive Endometrial Cancer (EC)Cohort 5: Subjects with HER2-positive Ovarian Cancer (OC)Cohort 6: Subjects with HER2-positive Urothelial Cancers (UC)
- Interventions
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- SystImmune Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06714617
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Phase 1
Recruiting
- Conditions
- Endometrial CancerCervical CancerUrothelial CarcinomaOvarian CancerGastroesophageal-junction CancerEsophageal CancerLung CancerBiliary Tract CancerBreast CancerGastric Cancer
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- SystImmune Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT06293898
- Locations
- 🇺🇸
SystImmune Recruiting Center, Fairfax, Virginia, United States
🇺🇸SystImmune Recruiting Site, Houston, Texas, United States
Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Phase 1
Recruiting
- Conditions
- Small Cell Lung CancerNSCLCLung CancerNPCNon Small Cell Lung CancerEsophageal CancerNasopharyngeal CancerBreast CancerSCLC
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- SystImmune Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT05983432
- Locations
- 🇺🇸
SystImmune Recruiting Center, Houston, Texas, United States
🇪🇸SystImmune Recruiting Site, Madrid, Spain
© Copyright 2025. All Rights Reserved by MedPath